



RGWL/22-23/

18th October, 2022

To BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai 400001 Scrip Code – 517522	To National Stock Exchange of India Limited ‘Exchange Plaza’, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 Symbol - RAJRATAN
--	---

Subject – Schedule of Conference Call

Dear Sirs,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 kindly note that, the B&K Securities is arranging a conference call to discuss the performance for quarter and half year ended 30th September, 2022, for analysts and investors on **Friday, 21st October, 2022 at 16.30 Hrs IST**

The Registration link for same is as follows –

<https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=8306563&linkSecurityString=26d84770df>

Detailed invitation containing telephone number, contact details, etc. for the said conference call is enclosed.

Kindly take the same on your records.

Thanking You,
Yours Faithfully

For Rajratan Global Wire Limited

Shubham Jain
Company Secretary & Compliance Officer



CONCALL INVITE

B&K Securities shall hold
a Conference Call of

Rajratan Global Wire Limited

to discuss the 2QFY23 Financial Performance
on **Friday, 21st October 2022** at **16:30 Hrs IST**

Management Representatives:

Mr. Sunil Chordia – Chairman & Managing Director

Mr. Hitesh Jain – Chief Financial Officer, India

Mr. Yashovardhan Chordia – MD, Rajratan Thailand

Mr. Pranay Jain – Chief Financial Officer, Thailand

You are cordially invited

Diamond Pass Link

<https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=8306563&linkSecurityString=26d84770df>

Universal Dial-in Numbers

+91 22 6280 1222 / +91 22 7115 8123

International Toll Free:

Argentina: 0080014243444 | Australia: 1800053698 | Belgium: 0080014243444

Canada: 01180014243444 | China: 4008428405 | France: 0800914745 | Germany: 0080014243444

Hong Kong: 800964448 | Italy: 0080014243444 | Japan: 00531161110

Netherlands: 08000229808 | Poland: 008001124248 | Singapore: 8001012045

South Korea: 00180014243444 | Sweden: 0080014243444 | Thailand: 00180014243444

UK: 08081011573 | USA: 18667462133

International Toll

HongKong: +852 30186877 | Japan: +81 345899421 | Singapore: +65 31575746

SouthAfrica: +27 110623033 | UK: +44 2034785524 | USA: +1 3233868721

For further information, please contact

Mr. Sailesh Raja

Batlivala & Karani Securities India Pvt. Ltd.

+91 77081 76999 / +91 75502 27208

sailsh.raja@bksec.com

Regards

B&K Research

research.equities@bksec.com

+91-22-4031 7000

Disclaimer

This report was prepared, approved, published and distributed by Batlivala & Karani Securities India Private Limited ("B&K") located outside of the United States (a "non-US Group Company"), which accepts responsibility for its contents. It is distributed in the U.S. by Enclave Capital, a U.S. registered broker dealer, on behalf of B&K, only to major U.S. institutional investors (as defined in Rule 15a-6 under the U.S. Securities Exchange Act of 1934 (the "Exchange Act") pursuant to the exemption in Rule 15a-6. Neither the report nor any analyst who prepared or approved the report is subject to U.S. legal requirements or the Financial Industry Regulatory Authority, Inc. ("FINRA") or other regulatory requirements pertaining to research reports or research analysts. No non-US Group Company is registered as a broker-dealer under the Exchange Act or is a member of the Financial Industry Regulatory Authority, Inc. or any other U.S. self-regulatory organization. Outside the United States, this report is distributed by B&K or an authorized affiliate of B&K.

The report has been compiled or arrived from sources believed to be reliable and in good faith, but no representation or warranty, express or implied is made as to their accuracy, completeness or correctness. B&K has not verified the factual accuracy, assumptions, calculations or completeness of the information. Accordingly, B&K accepts no liability whatsoever for any direct or consequential loss or damage arising from (i) the use of this communication (ii) reliance of any information contained herein, (iii) any error, omission or inaccuracy in any such information or (iv) any action resulting there from. B&K provides the information for the purpose of the intended recipient's analysis and review and recipients are advised to verify the factual accuracy, assumptions, calculations and completeness of the information.

This report was produced by B&K solely for information purposes and for the use of the recipient. It is not to be reproduced, redistributed under any circumstances and is not to be copied or made available to any person other than the recipient. All estimates, expressions of opinion and other subjective judgments contained herein are made as of the date of this document. Emerging securities markets may be subject to risks significantly higher than more established markets. In particular, the political and economic environment, company practices and market prices and volumes may be subject to significant variations. The ability to assess such risks may also be limited due to significantly lower information quantity and quality. By accepting this document, you agree to be bound by all the foregoing provisions. This document does not constitute an offer of, or an invitation by or on behalf of B&K or its affiliates or any other company to any person, to buy or sell any security.

The views of any Analyst reflected in this report are given in compliance with the Research Analyst Regulations, 2014. All analysts covering the securities/companies mentioned in this report have complied with the appropriate set of rules, regulations & procedures in their detailed coverage report(s) of the respective securities/companies. It is important to note that any dispute with respect to this Research Report, would not have access to stock exchange investor redressal forum or arbitration mechanism.

Analyst Certification

Each of the analysts identified in this report certifies, with respect to the companies or securities that the individual analyses, that (1) the views expressed in this report reflect his or her personal views about all of the subject companies and securities and (2) no part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this report.

1. B&K or its Affiliates have not recently been the beneficial owners of 1% or more of the securities mentioned in this report.
2. B&K or its Affiliates have not managed or co-managed a public offering of the securities mentioned in the report in the past 12 months.
3. B&K or its Affiliates have not received compensation for investment banking services from the issuer of these securities in the past 12 months and do not expect to receive compensation for investment banking services from the issuer of these securities within the next three months.
4. However, one or more person of B&K or its affiliates may, from time to time, have a long or short position in any of the securities mentioned herein and may buy or sell those securities or options thereon either on their own account or on behalf of their clients.
5. B&K or its Affiliates may, to the extent permitted by law, act upon or use the above material or the conclusions stated above or the research or analysis on which they are based before the material is published to recipients and from time to time provide investment banking, investment management or other services for or solicit to seek to obtain investment banking, or other securities business from, any entity referred to in this report.
6. As of the publication of this report, Enclave Capital does not make a market in the subject securities.

Important US Regulatory Disclosures on Subject Companies

Enclave Capital is the distributor of this document in the United States of America. Any US customer wishing to effect transactions in any securities referred to herein or options thereon should do so only by contacting a representative of Enclave Capital and any transaction effected by a U.S. customer in the securities described in this report must be effected through Enclave Capital (19 West 44th Street, suite 1700, New York, NY 10036). Tel No: (646) 454 8600).